PositiveSingles.com - the best, most trusted and largest anonymous STD dating site!
PositiveSingles.com - the best, most trusted and largest anonymous STD dating site!

Google Search

Showing posts with label Against. Show all posts
Showing posts with label Against. Show all posts

Monday, June 24, 2013

Eyeball Licking: a New Herpes Risk Worries Doctors; polyDNA Recommends Gene-Eden-VIR against the Latent Herpes Virus

Rochester, NY (PRWEB) June 22, 2013

Eyeball licking has become a fad in Japan and may spread to young lovers and Japanese anime fans in the United States. This is a dangerous trend since licking the eyeball of a loved one may expose the person whose eye is being licked to the herpes virus.

“If the person doing the licking has something such as the herpes virus, it too, can easily be passed onto the other person through the eyeball.” - Dr Phillip Rizzuto, American Academy of Ophthalmology (1)

What kinds of symptoms result from a herpes eye infection?

According to Patient.co.uk, symptoms include: red eye, photophobia, pain, epiphora (tearing), blurred vision, May have generalised symptoms of a viral illness (upper respiratory tract infection, mild fever, malaise), and more. (2)

“The CDC states that persistent hand-washing and avoiding eye-rubbing are the best ways for non-eyeball lickers to prevent spreading the contagion.” (1)

“We recommend against licking an eyeball, or having your own eyeball licked. While some people might find this practice erotic, it can lead to bacterial infections like “pink eye” and of course, it can lead to a herpes infection. Regardless of where the herpes infection comes from, people need a remedy that attacks the latent herpes virus, before it becomes active. ” – Mike Evans, polyDNA

polyDNA recommends Gene-Eden-VIR to individuals afraid of a herpes infection. Gene-Eden-VIR boosts the immune system and helps it attack and eliminate the latent herpes virus. A recent post marketing clinical study showed that Gene-Eden-VIR is safe and effective. Up to 70% of those studied reported a decrease in viral symptoms. (3)

Each ingredient of Gene-Eden-VIR was chosen through a scientific approach. Scientists scanned thousands of scientific and medical papers published in various medical and scientific journals around the world to identify the safest, most effective natural ingredients that target the latent form of herpes. (4)

To learn more about Gene-Eden-VIR and herpes, visit http://www.gene-eden-kill-virus.com/Herpes-Remedy.php. All orders of Gene-Eden-VIR are completely confidential, and no information is shared or sold to any third party. Privacy is assured.

Reference:

(1)    http://atlanta.cbslocal.com/2013/06/13/eyeball-licking-fetish-among-youth-worries-medical-experts/
(2)    http://www.patient.co.uk/doctor/Herpes-Simplex-Eye-Infections.htm
(3)    http://www.cbcd.net/Gene-Eden-VIR-Clinical-Study.php
(4)    http://gene-eden-kill-virus.com/studies.php
polyDNA is a biotechnology company that develops dietary supplements using the unique scientific method developed by Dr. Hanan Polansky, which is based on Computer Intuition.

In addition to his unique scientific method, Dr. Polansky published the highly acclaimed scientific discovery, called Microcompetition with Foreign DNA. The discovery explains how foreign DNA fragments, and specifically, DNA of latent viruses, cause most major diseases.

polyDNA developed Gene-Eden-VIR , an antiviral natural remedy that helps the immune system kill latent viruses.



View the original article here

Saturday, May 11, 2013

New Study: Herpes Zoster May Lead to Stroke; polyDNA Recommends Gene-Eden-VIR against VZV

Since 1 out of every 3 people in the United States will develop shingles, polyDNA recommends Gene-Eden-VIR to kill VZV as early as possible.

Rochester, NY (PRWEB) April 23, 2013

In a new study from the Journal of Neurovirology it was found that "Virological confirmation of varicella zoster virus (VZV) vasculopathy is provided by presence of virus in the cerebral arteries. Thus, the presence of VZV antigen in cerebral arteries of patients with stroke is likely to be clinically significant."(1)

In simple terms this means that the connection between the herpes zoster virus and suffering a stroke is very important.

Another study also reported that a herpes zoster attack lowers the survival rate. (2)

This is important information since, “…1 out of every 3 people in the United States will develop shingles, also known as zoster or herpes zoster.” (3) In fact, anyone who has ever had chickenpox is at risk for developing herpes zoster. Even children can develop this affliction after a case of chickenpox. However, “the risk of disease increases as a person gets older” (3) as does the risk of suffering a debilitating stroke.

The public, especially those over the age of 65, should be aware of the dangers and risks of a herpes zoster attack. polyDNA recommends that these individuals educate themselves about Gene-Eden-VIR, a natural remedy designed to boost the immune system against latent VZV.

“Since VZV is the only recognized human virus able to replicate in cerebral arteries, (4) I feel like anyone with an increased risk of developing shingles should consider doing what they can to reduce the levels of VZV virus in their systems. No one wants to suffer a stroke.” – Mike Evans, polyDNA

Currently, doctors only prescribe Blood platelet inhibitors such as Aspirin, Dipyridamole, Ticlopidine, Clopidogrel and Sulfinpyrazone are effective in reducing the risk for stroke.(5) However, these are for thinning the blood and are used to help prevent blood clots from forming inside arteries in the brain. These drugs do nothing against the herpes zoster virus.

In contrast, Gene-Eden-VIR was designed to boost the immune system against viruses like latent VZV. "The key to your health is to reduce the level of the latent viruses in your body to harmless levels." - Dr. Hanan Polansky

In a post marketing clinical study, Gene-Eden-VIR was shown to be safe and highly effective against the latent herpes zoster virus. Over 70% of Gene-Eden-VIR users reported a reduction in VZV symptoms. (6)

Each capsule of Gene-Eden-VIR contains a patented formula of five all natural ingredients including selenium, camellia sinesis extract, quercetin, cinnamomum extract, and licorice extract. In addition, each bottle is GMP Certified. (7)

To learn more about Gene-Eden-VIR, the only product on the market today that helps the body target the latent herpes zoster virus and that is scientifically backed by published material, visit http://www.gene-eden-kill-virus.com.

References:

(1) http://www.ncbi.nlm.nih.gov/pubmed/23456953


(2) http://f1000.com/prime/1165403


(3) http://www.cdc.gov/shingles/about/overview.html


(4) Kleinschmidt-DeMasters BK, Gilden DH. Varicella-zoster virus infections of the nervous system: clinical and pathologic correlates. Arch Pathol Lab Med. 2001; 125: 770–780.


(5) http://www.medicalnewstoday.com/articles/184601.php


(6) http://www.cbcd.net/Gene-Eden-VIR-Clinical-Study.php


(7) http://www.gene-eden-kill-virus.com/studies.php

polyDNA is a biotechnology company that develops dietary supplements using the unique scientific method developed by Dr. Hanan Polansky, which is based on Computer Intuition.

In addition to his unique scientific method, Dr. Polansky published the highly acclaimed scientific discovery called Microcompetition with Foreign DNA.

The discovery explains how foreign DNA fragments and specifically DNA of latent viruses cause most major diseases. polyDNA developed Gene-Eden-VIR, an antiviral natural remedy that helps the immune system kill latent viruses.

Mike Davis
PolyDNA
5852509999
Email Information


View the original article here

Friday, May 10, 2013

New Study: Herpes, the STD, May Lead to Tumors of the Heart; polyDNA Recommends Gene-Eden-VIR against the Herpes Virus

A herpes virus infection may cause primary tumors of the heart in adults. polyDNA recommends killing the herpes virus as early as possible.

Rochester, NY (PRWEB) April 14, 2013

Herpes is usually associated with genital sores, fever blisters, cold sores, sexually transmitted infections and social stigmas. However, a new study links both genital herpes and oral herpes to the development of tumors of the heart.

“This study has shown that HSV DNA is detected significantly more frequently in cardiac myxomas than in their normal counterparts.” In addition, the researchers reported that “…the detection of HSV-2 as the infectious agent in two myxoma cases reflects a novel finding.” [1]

This is important because myxomas, tumors of primitive connective tissue, are the most common type of tumor in the heart. [2]

“Of particular interest is the recognition of HSV-2 as a potential cardiovascular pathogen. The virus has been implicated in coronary artery disease and carotid atherosclerosis.” – (Journal of Biomedicine and Biotechnology)

Common clinical manifestations of myxomas are strokes, peripheral or pulmonary embolization, fever, weight loss, high sedimentation rate, anemia, and leucocytosis. [3]

The public should be aware of the fact that herpes could lead to the development of heart tumors over time. polyDNA recommends that people educate themselves about Gene-Eden-VIR, a natural remedy against the latent herpes virus.

By helping the body’s immune system target the latent herpes virus, people also lower their risk of developing fever blisters, cold sores, genital herpes symptoms, and may also help prevent strokes, fever, anemia, athererosclerosis and the development of heart tumors.

"The key to your health is to reduce the level of the chronic viruses in your body to harmless levels." - Dr. Hanan Polansky

In a post marketing clinical study, Gene-Eden-VIR was shown to be safe and highly effective against the latent herpes virus. Over 70% of Gene-Eden-VIR users reported a reduction in herpes symptoms. (4)

Each capsule of Gene-Eden-VIR contains a patented formula of five all natural ingredients including selenium, camellia sinesis extract, quercetin, cinnamomum extract, and licorice extract. In addition, each bottle is GMP Certified. (5)

To learn more about Gene-Eden-VIR, the only product on the market today that helps the body target the latent herpes virus and that is scientifically backed by published material, visit http://www.gene-eden-kill-virus.com.

Reference:

(1) http://www.hindawi.com/journals/bmri/2012/823949/

(2) Dorland’s Medical Dictionary

(3) K. A. Ekmektzoglou, G. F. Samelis, and T. Xanthos, “Heart and tumors: location, metastasis, clinical manifestations, diagnostic approaches and therapeutic considerations,” Journal of Cardiovascular Medicine, vol. 9, no. 8, pp. 769–777, 2008.

(4) http://www.cbcd.net/Gene-Eden-VIR-Clinical-Study.php

(5)http://www.gene-eden-kill-virus.com/studies.php

###

polyDNA is a biotechnology company that develops dietary supplements using the unique scientific method developed by Dr. Hanan Polansky, which is based on Computer Intuition.

In addition to his unique scientific method, Dr. Polansky published the highly acclaimed scientific discovery, called Microcompetition with Foreign DNA.

The discovery explains how foreign DNA fragments, and specifically, DNA of latent viruses, cause most major diseases. polyDNA developed Gene-Eden-VIR (), an antiviral natural remedy that helps the immune system kill latent viruses.

Mike Davis
PolyDNA
5852509999
Email Information


View the original article here

Monday, April 15, 2013

Herpes Remedy, Gene-Eden-VIR, Can Be Effective Against Herpes Related Memory Problems

1 out of 4 women infected with the herpes virus suffer from memory problems. polyDNA’s herpes remedy, Gene-Eden-VIR, helps immune system kill HSV-1, and therefore may be effective in treating memory problems.

Rochester, NY (PRWEB) April 01, 2013

polyDNA researchers have linked the ingredients of Gene-Eden-VIR, an all natural, scientific herpes remedy, with an improvement of cognitive functions. While conducting research into herpes related illnesses, polyDNA found that women with a herpes type 1 infection have a significantly higher risk of developing memory problems and other cognitive issues. [1]

This is even more noteworthy since “60 percent of U.S. men and women between the ages of 14 and 49 carry the herpes simplex type 1 virus.” [2]

Cinnamon is a natural antiviral. [3] Moreover, cinnamon has also been found to naturally boost memory and other cognitive functions by inhibiting tau aggregation and filament formation, which are hallmarks of Alzheimer's disease (AD). [4]

Gene-Eden-VIR’s all natural ingredients include cinnamon. In fact, Gene-Eden-VIR contains five all natural antiviral ingredients including cinnamon, selenium, quercetin, and licorice extract.

Mike Evans from polyDNA said “The fact that nature has given us an all natural ingredient that has scientifically been shown to combat both herpes as well as prevent other cognitive problems is amazing. It’s even more amazing since herpes can also cause brain problems. When we developed Gene-Eden-VIR, we knew we wanted it to be a natural remedy with as broad an application as possible. This research shows exactly how Gene Eden can take on two seemingly unrelated illnesses, focus on the source of those illnesses, and then work to combat those illnesses’ origin.”

The public should be aware of the relationship between herpes and cognitive problems and take steps to prevent those problems from arising. polyDNA recommends boosting the immune system against a latent herpes infection through the use the all natural herpes remedy, Gene-Eden-VIR.

A recent post marketing clinical study showed that Gene-Eden-VIR is effective against the latent herpes virus. By helping the body's immune system target the latent herpes virus, people also lower their risk of developing fever blisters, cold sores, or genital herpes symptoms. [5]

Gene-Eden-VIR is highly effective against the latent herpes virus, each ingredient was chosen through a scientific approach. Scientists scanned thousands of scientific and medical papers published in various medical and scientific journals around the world to identify the safest, most effective natural ingredients that target the latent forms of both HSV-1 and HSV-2. [6]

To learn more about Gene-Eden-VIR, visit http://www.gene-eden-kill-virus.com.

References:

1: Infectious burden and cognitive function

2: For Many, Herpes May Cause Memory Loss Along with Cold Sores

3 : In vitro and in vivo activity of eugenol on human herpesvirus

4 : Cinnamon extract inhibits tau aggregation associated with Alzheimer's disease in vitro

5 : Gene-Eden-VIR is Antiviral: Results of a Post Marketing Clinical Study

6 : The antiviral effect of Gene-Eden

polyDNA is a biotechnology company that develops dietary supplements using the unique scientific method developed by Dr. Hanan Polansky, which is based on Computer Intuition.

In addition to his unique scientific method, Dr. Polansky published the highly acclaimed scientific discovery, called Microcompetition with Foreign DNA. The discovery explains how foreign DNA fragments, and specifically, DNA of latent viruses, cause most major diseases.

polyDNA developed Gene-Eden-VIR , an antiviral natural remedy that helps the immune system kill latent viruses.

Mike Davis
PolyDNA
5852509999
Email Information


View the original article here

Thursday, December 6, 2012

Compound discovered that boosts effect of vaccines against HIV and flu

ScienceDaily (Aug. 26, 2012) — Oxford University scientists have discovered a compound that greatly boosts the effect of vaccines against viruses like flu, HIV and herpes in mice.

An 'adjuvant' is a substance added to a vaccine to enhance the immune response and offer better protection against infection.

The Oxford University team, along with Swedish and US colleagues, have shown that a type of polymer called polyethyleneimine (PEI) is a potent adjuvant for test vaccines against HIV, flu and herpes when given in mice.

The researchers were part-funded by the UK Medical Research Council and report their findings in the journal Nature Biotechnology.

Mice given a single dose of a flu vaccine including PEI via a nasal droplet were completely protected against a lethal dose of flu. This was a marked improvement over mice given the flu vaccine without an adjuvant or in formulations with other adjuvants.

The Oxford researchers now intend to test the PEI adjuvant in ferrets, a better animal model for studying flu. They also want to understand how long the protection lasts for. It is likely to be a couple of years before a flu vaccine using the adjuvant could be tested in clinical trials in humans, the researchers say.

'Gaining complete protection against flu from just one immunisation is pretty unheard of, even in a study in mice,' says Professor Quentin Sattentau of the Dunn School of Pathology at Oxford University, who led the work. 'This gives us confidence that PEI has the potential to be a potent adjuvant for vaccines against viruses like flu or HIV, though there are many steps ahead if it is ever to be used in humans.'

HIV, flu and herpes are some of the most difficult targets to develop vaccines against. HIV and flu viruses are able to change and evolve to escape immune responses stimulated by vaccines. There aren't any effective vaccines against HIV and herpes as yet, and the flu vaccine needs reformulating each year and doesn't offer complete protection to everyone who receives it. Finding better adjuvants could help in developing more effective vaccines against these diseases.

Most vaccines include an adjuvant. The main ingredient of the vaccine -- whether it is a dead or disabled pathogen, or just a part of the virus or bacteria causing the disease -- primes the body's immune system so it knows what to attack in case of infection. But the adjuvant is needed as well to stimulate this process.

While the need for adjuvants in vaccines has been recognised for nearly 100 years, the way adjuvants work has only recently been understood. The result has been that only a small set of adjuvants is used in current vaccines, often for historical reasons.

The most common adjuvant by far is alum, an aluminium-containing compound that has been given in many different vaccines worldwide for decades. However, alum is not the most potent adjuvant for many vaccine designs.

'There is a need to develop new adjuvants to get the most appropriate immune response from vaccines,' says Professor Sattentau, who is also a James Martin Senior Fellow at the Oxford Martin School, University of Oxford.

The Oxford University team found that PEI, a standard polymer often used in genetic and cell biology, has strong adjuvant activity.

When included in a vaccine with a protein from HIV, flu or herpes virus, mice subsequently mounted a strong immune response against that virus. The immune response was stronger than with other adjuvants that are currently being investigated.

The team also showed that PEI is a potent adjuvant in rabbits, showing the effect is not just specific to mice and could be general.

Another potential advantage of PEI is that it works well as an adjuvant for 'mucosal vaccines'. These vaccines are taken up the nose or in the mouth and absorbed through the mucus-lined tissues there, getting rid of any pain and anxiety from a needle. Mucosal vaccines may also be better in some ways as mucosal tissues are the sites of infection for these diseases (airways for respiratory diseases, genital mucosa for HIV and herpes).

Professor Sattentau suggests that: 'In the best of all possible worlds, you could imagine people would have one dose of flu vaccine that they'd just sniff up their nose or put under their tongue. And that would be it: no injections and they'd be protected from flu for a number of years.

'It's just a vision for the future at the moment, but this promising adjuvant suggests it is a vision that is at least possible.'

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

Story Source:

The above story is reprinted from materials provided by University of Oxford, via EurekAlert!, a service of AAAS.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.

Note: If no author is given, the source is cited instead.

Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.


View the original article here

Wednesday, August 29, 2012

Drug against AIDS could be effective against herpesvirus

ScienceDaily (Sep. 24, 2010) — Scientists at the Institute for Research in Biomedicine (IRB Barcelona) headed by the coordinator of the Structural and Computational Biology Programme, Miquel Coll, have published a new study that demonstrates that raltegravir, the drug approved in 2007 for the treatment of AIDS that is sold by Merck under the name Isentress, cancels the function of an essential protein for the replication of one kind of herpes virus. This study, published in the journal Proceedings of the National Academies of Sciences (PNAS), is the first step towards the development of a drug against the entire herpesvirus family.

"These results have a clear medical impact for three reasons," explains Miquel Coll, also a CSIC research professor. "First, humans do not have the viral protein that is affected, thus this would allow a highly specific drug that does not show the secondary effects that other drugs may have. Second, the inhibitor is not toxic for humans when administered at therapeutic concentrations because it is already on the market and thus toxicity tests are facilitated; and third, we have data that indicate that all herpes viruses have this protein. Therefore, it could be a valid target against all Herpesviridae."

Herpesviruses include pathogens such as herpes simplex 1 and 2, the virus that causes chickenpox otherwise known as zoster virus, the Epstein-Barr virus -associated with several types of cancer -, the roseola virus, the cytomegalovirus and the herpes virus associated with Kaposi sarcoma -in AIDS patients -. The human cytomegalovirus (HCMV), on which the study was performed, causes neurological defects in 1% of neonates in developed countries. It also produces retinitis that deteriorates into blindness in 25% of subjects with AIDS, defects in the brains and central nervous systems of young adults, inflammation of the colon -also in those with AIDS -, mononucleosis and serious diseases of the throat. Although 90% of adults carry HCMV, this virus is opportunistic, acting in people with weakened immune systems such as in cancer and AIDS patients, recipients of organ transplants and neonates.

Blocking viral replication

To replicate, the herpes virus enters the nucleus of a cell where it uses the cell machinery to copy its DNA several times into a single large chain. Once this copy has been made, acts a complex called terminase, formed by three protein subunits. The terminase cuts the new DNA into small fragments, the size of a single viral genome, and introduces these into empty shells (capsids) that have developed in the cell nucleus. Then, the new viruses leave the cell to continue infection. The researchers resolved the 3D structure of one part of the terminase and when they observed that it resembled the integrase of the AIDS virus, for which drugs are available, they tested it against the herpes virus protein. Thus they discovered that raltegravir acts on the subunit UL89 of the terminase and cancels the scissor function, which is required for viral replication.

The assays were performed directly on the protein in test tubes. "Now we must do the assays on whole infected cells, improve the effect of the drug and validate that it is also effective for other kinds of herpes viruses," explains Miquel Coll, whose lab has patented this second application for raltegravir. To resolve the 3D structure of the target protein, the scientists have used a state-of-the-art high-performance protein expression technique, with the collaboration with Darren Hart's group at EMBL in Grenoble, where 18,000 clones or different fragments of the protein have been tested. They have also used the Grenoble synchrotron to obtain the structural data. The study has lasted five years and forms part of the European project SPINE-2 complexes.

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

Story Source:

The above story is reprinted from materials provided by Institute for Research in Biomedicine-IRB.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.

Journal Reference:

M. Nadal, P. J. Mas, A. G. Blanco, C. Arnan, M. Sola, D. J. Hart, M. Coll. Structure and inhibition of herpesvirus DNA packaging terminase nuclease domain. Proceedings of the National Academy of Sciences, 2010; 107 (37): 16078 DOI: 10.1073/pnas.1007144107

Note: If no author is given, the source is cited instead.

Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.


View the original article here

Saturday, May 5, 2012

Drug against AIDS could be effective against herpesvirus

ScienceDaily (Sep. 23, 2010) — Scientists at the Institute for Research in Biomedicine (IRB Barcelona) headed by the coordinator of the Structural and Computational Biology Programme, Miquel Coll, have published a new study that demonstrates that raltegravir, the drug approved in 2007 for the treatment of AIDS that is sold by Merck under the name Isentress, cancels the function of an essential protein for the replication of one kind of herpes virus. This study, published in the journal Proceedings of the National Academies of Sciences (PNAS), is the first step towards the development of a drug against the entire herpesvirus family.

"These results have a clear medical impact for three reasons," explains Miquel Coll, also a CSIC research professor. "First, humans do not have the viral protein that is affected, thus this would allow a highly specific drug that does not show the secondary effects that other drugs may have. Second, the inhibitor is not toxic for humans when administered at therapeutic concentrations because it is already on the market and thus toxicity tests are facilitated; and third, we have data that indicate that all herpes viruses have this protein. Therefore, it could be a valid target against all Herpesviridae."

Herpesviruses include pathogens such as herpes simplex 1 and 2, the virus that causes chickenpox otherwise known as zoster virus, the Epstein-Barr virus -associated with several types of cancer -, the roseola virus, the cytomegalovirus and the herpes virus associated with Kaposi sarcoma -in AIDS patients -. The human cytomegalovirus (HCMV), on which the study was performed, causes neurological defects in 1% of neonates in developed countries. It also produces retinitis that deteriorates into blindness in 25% of subjects with AIDS, defects in the brains and central nervous systems of young adults, inflammation of the colon -also in those with AIDS -, mononucleosis and serious diseases of the throat. Although 90% of adults carry HCMV, this virus is opportunistic, acting in people with weakened immune systems such as in cancer and AIDS patients, recipients of organ transplants and neonates.

Blocking viral replication

To replicate, the herpes virus enters the nucleus of a cell where it uses the cell machinery to copy its DNA several times into a single large chain. Once this copy has been made, acts a complex called terminase, formed by three protein subunits. The terminase cuts the new DNA into small fragments, the size of a single viral genome, and introduces these into empty shells (capsids) that have developed in the cell nucleus. Then, the new viruses leave the cell to continue infection. The researchers resolved the 3D structure of one part of the terminase and when they observed that it resembled the integrase of the AIDS virus, for which drugs are available, they tested it against the herpes virus protein. Thus they discovered that raltegravir acts on the subunit UL89 of the terminase and cancels the scissor function, which is required for viral replication.

The assays were performed directly on the protein in test tubes. "Now we must do the assays on whole infected cells, improve the effect of the drug and validate that it is also effective for other kinds of herpes viruses," explains Miquel Coll, whose lab has patented this second application for raltegravir. To resolve the 3D structure of the target protein, the scientists have used a state-of-the-art high-performance protein expression technique, with the collaboration with Darren Hart's group at EMBL in Grenoble, where 18,000 clones or different fragments of the protein have been tested. They have also used the Grenoble synchrotron to obtain the structural data. The study has lasted five years and forms part of the European project SPINE-2 complexes.

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

Story Source:

The above story is reprinted from materials provided by Institute for Research in Biomedicine-IRB, via AlphaGalileo.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.

Journal Reference:

M. Nadal, P. J. Mas, A. G. Blanco, C. Arnan, M. Sola, D. J. Hart, M. Coll. Structure and inhibition of herpesvirus DNA packaging terminase nuclease domain. Proceedings of the National Academy of Sciences, 2010; 107 (37): 16078 DOI: 10.1073/pnas.1007144107

Note: If no author is given, the source is cited instead.

Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.


View the original article here

Wednesday, April 11, 2012

Condoms Associated With Moderate Protection Against Herpes Simplex Virus 2

ScienceDaily (July 13, 2009) — Condom use is associated with a reduced risk of contracting herpes simplex virus 2, according to a report based on pooled analysis of data from previous studies.

Herpes simplex virus 2 (HSV-2) typically causes genital herpes, a chronic, life-long, viral infection. Although studies indicate that consistent condom use reduces the spread of HIV and other sexually transmitted diseases such as chlamydia and gonorrhea, the effectiveness of preventing the transmission of HSV-2 through condom use is less certain, according to background information in the article.

Emily T. Martin, M.P.H., Ph.D., of Children's Hospital Research Institute and the University of Washington, Seattle, and colleagues analyzed data from six HSV-2 studies to assess the effectiveness of condom use in preventing the virus. The studies included three candidate HSV-2 vaccine studies, an HSV-2 drug study, an observational sexually transmitted infection (STI) incidence study and a behavioral STI intervention study. These yielded results from 5,384 HSV-2-negative individuals (average age 29) at baseline for a combined total of 2,040,894 follow-up days.

More than 66 percent of those who took part in the six studies were male, 60.4 percent were white, 94.1 percent were heterosexual and most reported no prior STIs.

A total of 415 of the individuals acquired HSV-2 during follow-up. "Consistent condom users [used 100 percent of the time] had a 30 percent lower risk of HSV-2 acquisition compared with those who never used condoms," the authors write. "Risk of HSV-2 acquisition decreased by 7 percent for every additional 25 percent of the time that condoms were used during anal or vaginal sex." The risk of acquiring the virus increased significantly with increasing frequency of unprotected sex acts. There were no significant differences found in condom effectiveness between men and women.

"Based on findings of this large analysis using all available prospective data, condom use should continue to be recommended to both men and women for reducing the risk of HSV-2 acquisition," the authors conclude. "Although the magnitude of the protective effect was not as large as has been observed with other STIs, a 30 percent reduction in HSV-2 incidence can have a substantial benefit for individuals as well as a public health impact at the population level."

Funding for this project was provided by grants from the National Institutes of Health, National Institute of Allergy and Infectious Diseases. 

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

Story Source:

The above story is reprinted from materials provided by JAMA and Archives Journals.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.

Journal Reference:

Emily T. Martin, MPH; Elizabeth Krantz, MS; Sami L. Gottlieb, MD, MSPH; Amalia S. Magaret, PhD; Andria Langenberg, MD; Lawrence Stanberry, MD, PhD; Mary Kamb, MD, MPH; Anna Wald, MD, MPH. A Pooled Analysis of the Effect of Condoms in Preventing HSV-2 Acquisition. Arch Intern Med, 2009;169(13):1233-1240 [link]

Note: If no author is given, the source is cited instead.

Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.


View the original article here

Thursday, January 26, 2012

Vaccine Fails to Protect Against Herpes Transmission

A promising shot against herpes virus misses the mark. But antiviral drugs can control infection, if only for a short timeBIOPHOTO ASSOCIATES

Encouraged by the success of vaccines against human papillomavirus, researchers began developing a shot that they hoped would immunize women against another sexually transmitted virus, herpes. But the latest results, reported in the New England Journal of Medicine, aren’t encouraging.

The vaccine was designed to protect women against two forms of herpes, HSV1 and HSV2, and involved more than 8000 women between ages 18 and 30. Previous studies had shown the shot provided some protection against infection with the viruses, but the latest trial revealed that the vaccine was only mildly effective in preventing HSV-1 infections and not protective at all against HSV-2. None of the women had herpes at the start of the study, and were followed for 20 months to see if three doses of the shot prevented herpes infection due to normal sexual activity. Half of the women received the hepatitis A vaccine, which served as a control.

“I think this is the end of the vaccine,” the study’s co-author Dr. Peter Leone, an infectious disease expert at University of North Carolina Chapel Hill told msnbc.com.

MORE: How Many Patients Spread Herpes, But Don’t Even Know They Have It?

The study wasn’t a complete waste, however, since the researchers learned some new things about herpes infections that could improve future treatments. Most experts had thought that HSV-1 was primarily responsible for cold sores, while HSV-2 contributed to blisters on the genitals. The study showed, however, that women who didn’t receive the vaccine were more likely to contract genital herpes due to HSV-1.

That means that a vaccine able to protect against both HSV-1 and HSV-2 will be critical, and Leone and his team already have some ideas about how to develop one. While the current shot included snippets of herpes virus protein to alert the immune system, a more effective vaccine may need a more robust trigger, such as a weakened form of the virus, to elicit a proper virus-killing response.

In the meantime, there are drugs that can reduce the symptoms of herpes infections. In a study reported in the journal Lancet, scientists say that anti-viral drugs such as valacyclovir (Valtrex) and acyclovir (Zovirax) can lower the amount of HSV-2 virus shed in the body during infection. The effect isn’t long lasting, but can help in lowering risk of transmission. That’s why a vaccine is so important to truly control spread of the virus. According to the Centers for Disease Control, 16% of Americans between 14 and 49 are infected with HSV-2.


View the original article here

Tuesday, November 1, 2011

Tenofovir Vaginal Gel Protects Against Herpes - Medical News Today

Editor's Choice
Main Category: Sexual Health / STDs
Article Date: 21 Oct 2011 - 15:00 PDT window.fbAsyncInit = function() { FB.init({ appId: 'aa16a4bf93f23f07eb33109d5f1134d3', status: true, cookie: true, xfbml: true, channelUrl: 'http://www.medicalnewstoday.com/scripts/facebooklike.html'}); }; (function() { var e = document.createElement('script'); e.async = true; e.src = document.location.protocol + '//connect.facebook.net/en_US/all.js'; document.getElementById('fb-root').appendChild(e); }()); email icon email to a friend   printer icon printer friendly   write icon opinions  
5 stars5 stars
Anti-HIV drug, tenofovir, when formulated as a vaginal gel, was found to reduce herpes simplex risk in females, researchers from the USA, Belgium and Italy reported in the journal Cell Host & Microbe. The scientists explained that this is because of the higher concentrations that reach vaginal cells in the vaginal gel formulation, compared to the drug when taken orally.

The authors explained that tenofovir disables a DNA enzyme of the herpes virus - reverse transcriptase - thus stopping its spread.

This study was a collaboration between researchers from the Catholic University of Leuven (Belgium), the University of Rome (Italy), the National Institute of Child Health and Human Development (NICHD) (USA), and Gilead Sciences Inc.

A 2010 clinical trial found that tenofovir in vaginal gel form reduced the risk of HSV (herpes simplex virus) infections, as well as HIV infections in females. In this latest report, scientists say they can explain why.

Oral Tenofovir had been shown to undermine the reproduction of HIV. However, nobody knew it could block the genital herpes virus.

Leonid Margolis, Ph.D., NICHD, said:

"HIV infection is closely associated with herpes viral infection. When people with genital herpes are exposed to HIV, they are more likely to become infected than are people who do not carry the herpes virus. Human tissues convert tenofovir to a form that suppresses HIV. We found that this form of tenofovir also suppresses HSV. This discovery may help to identify drugs to treat the two viruses even more effectively."

Dr. Margolis explained that previously approved drugs which are found to have other therapeutic benefits, apart from those they were approved for, can save millions of dollars. A new compound has to undergo extensive testing for efficacy and safety before eventually coming onto the market several years and millions of dollars later. In the case of an already existing drug, most of the safety and other testing has already been done.

The scientist studied individual cells and groups of cells that had been infected with HSV. They found that tenofovir, in high concentrations blocked the virus' ability to reproduce.

Their study also showed that tenofovir does not damage cells, such as those that line the vagina. Vaginal cells are targeted by HIV and HSV.

Cellular enzymes convert tenofovir into another chemical form which suppresses both HIV and HSV. The new chemical form deactivates an enzyme that is crucial for the virus' reproduction.

They tested tenofovir in tissue samples, including tonsils and cervix. After 12 days they found that tenofovir-treated samples only had from 1% to 13% of viral levels compared to untreated samples. They also found that tenofovir blocked viral reproduction of both HIV and HSV simultaneously in infected tissue.

In laboratory experiments, they found that mice infected with the herpes virus had no herpes symptoms and lived longer when treated with tenofovir.

When tenofovir is taken orally, concentration levels in target cells are not high enough to affect HSV in any significant way, the authors explained.

Dr. Morgolis said:

"When using the gel, the amount of tenofovir on the affected tissues is about 100 times the amount in the body when taking tenofovir in pill form. That explains why its anti-herpes activity wasn't noticed before. Thus, under proper conditions, an anti-HIV drug becomes an anti-HSV drug."

Written by Christian Nordqvist
Copyright: Medical News Today
Not to be reproduced without permission of Medical News Today

Visit our sexual health / stds section for the latest news on this subject. "Topical Tenofovir, a Microbicide Effective against HIV, Inhibits Herpes Simplex Virus-2 Replication"
Graciela Andrei, Robert Snoeck, and Jan Balzarini (senior author), Joost van den Oord, Catholic University of Leuven; Emanuela Balestra, Carlo-Federico Perno (senior author), University of Rome; Tomas Cihlar, Gilead Sciences; and Andrea Lisco, Christophe Vanpouille, Andrea Introini, and Leonid Margolis (senior author) NICHD.
Cell Host & Microbe, Volume 10, Issue 4, 379-389, 20 October 2011 (10.1016/j.chom.2011.08.015) Please use one of the following formats to cite this article in your essay, paper or report:

MLA

Christian Nordqvist. "Tenofovir Vaginal Gel Protects Against Herpes." Medical News Today. MediLexicon, Intl., 21 Oct. 2011. Web.
30 Oct. 2011. APA

Please note: If no author information is provided, the source is cited instead.


posted by Sammy on 25 Oct 2011 at 9:51 pm

Women with herpes are unlucky to have herpes because it brings much trouble to their life; they are lucky at the same time because the virus will make them have less chance to have breast cancer.

| post followup | alert a moderator |


Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



View the original article here

Sunday, October 30, 2011

Tenofovir Vaginal Gel Protects Against Herpes

Anti-HIV drug, tenofovir, when formulated as a vaginal gel, was found to reduce herpes simplex risk in females, researchers from the USA, Belgium and Italy reported in the journal Cell Host & Microbe. The scientists explained that this is because of the higher concentrations that reach vaginal cells in the vaginal gel formulation, compared to the drug when taken orally.

The authors explained that tenofovir disables a DNA enzyme of the herpes virus - reverse transcriptase - thus stopping its spread.


This study was a collaboration between researchers from the Catholic University of Leuven (Belgium), the University of Rome (Italy), the National Institute of Child Health and Human Development (NICHD) (USA), and Gilead Sciences Inc.


A 2010 clinical trial found that tenofovir in vaginal gel form reduced the risk of HSV (herpes simplex virus) infections, as well as HIV infections in females. In this latest report, scientists say they can explain why.


Oral Tenofovir had been shown to undermine the reproduction of HIV. However, nobody knew it could block the genital herpes virus.


Leonid Margolis, Ph.D., NICHD, said:


"HIV infection is closely associated with herpes viral infection. When people with genital herpes are exposed to HIV, they are more likely to become infected than are people who do not carry the herpes virus. Human tissues convert tenofovir to a form that suppresses HIV. We found that this form of tenofovir also suppresses HSV. This discovery may help to identify drugs to treat the two viruses even more effectively."

Dr. Margolis explained that previously approved drugs which are found to have other therapeutic benefits, apart from those they were approved for, can save millions of dollars. A new compound has to undergo extensive testing for efficacy and safety before eventually coming onto the market several years and millions of dollars later. In the case of an already existing drug, most of the safety and other testing has already been done.


The scientist studied individual cells and groups of cells that had been infected with HSV. They found that tenofovir, in high concentrations blocked the virus' ability to reproduce.


Their study also showed that tenofovir does not damage cells, such as those that line the vagina. Vaginal cells are targeted by HIV and HSV.


Cellular enzymes convert tenofovir into another chemical form which suppresses both HIV and HSV. The new chemical form deactivates an enzyme that is crucial for the virus' reproduction.


They tested tenofovir in tissue samples, including tonsils and cervix. After 12 days they found that tenofovir-treated samples only had from 1% to 13% of viral levels compared to untreated samples. They also found that tenofovir blocked viral reproduction of both HIV and HSV simultaneously in infected tissue.


In laboratory experiments, they found that mice infected with the herpes virus had no herpes symptoms and lived longer when treated with tenofovir.


When tenofovir is taken orally, concentration levels in target cells are not high enough to affect HSV in any significant way, the authors explained.


Dr. Morgolis said:


"When using the gel, the amount of tenofovir on the affected tissues is about 100 times the amount in the body when taking tenofovir in pill form. That explains why its anti-herpes activity wasn't noticed before. Thus, under proper conditions, an anti-HIV drug becomes an anti-HSV drug."

Written by Christian Nordqvist
Copyright: Medical News Today
Not to be reproduced without permission of Medical News Today

Visit our sexual health / stds section for the latest news on this subject. "Topical Tenofovir, a Microbicide Effective against HIV, Inhibits Herpes Simplex Virus-2 Replication"
Graciela Andrei, Robert Snoeck, and Jan Balzarini (senior author), Joost van den Oord, Catholic University of Leuven; Emanuela Balestra, Carlo-Federico Perno (senior author), University of Rome; Tomas Cihlar, Gilead Sciences; and Andrea Lisco, Christophe Vanpouille, Andrea Introini, and Leonid Margolis (senior author) NICHD.
Cell Host & Microbe, Volume 10, Issue 4, 379-389, 20 October 2011 (10.1016/j.chom.2011.08.015) Please use one of the following formats to cite this article in your essay, paper or report:

MLA

Christian Nordqvist. "Tenofovir Vaginal Gel Protects Against Herpes." Medical News Today. MediLexicon, Intl., 21 Oct. 2011. Web.
30 Oct. 2011. APA

Please note: If no author information is provided, the source is cited instead.


posted by Sammy on 25 Oct 2011 at 9:51 pm

Women with herpes are unlucky to have herpes because it brings much trouble to their life; they are lucky at the same time because the virus will make them have less chance to have breast cancer.


| post followup | alert a moderator |



Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.


If you write about specific medications or operations, please do not name health care professionals by name.


All opinions are moderated before being included (to stop spam)


Contact Our News Editors


For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:


Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



View the original article here

Tuesday, July 12, 2011

Protecting Against Herpes - Testing Is the First Step


Remember that movie named Mask with Cher and the kid with the elephant man disease? Geez, imagine being born that way and having to face the world each and every day with a disfigured face? Imagine the heartache and pain that this poor kid suffered? Obviously, having a herpes sore on your lip is nowhere near the existential agony that this poor kid had to go through, but some people infected with herpes do feel ostracized and singled-out for comments and ridicule. If you are engaging in any form of sexual activity, remember how important regular and routine testing is to keeping yourself as healthy and happy as possible.

Why put yourself in the position of having your behavior written on your body for all to see? There's no good reason, especially when STD clinics are so up-to-date and good at what they do; that is, testing and treating all forms of sexual illness. Growing up with a cold sore breaking out once a year was bad enough. Feigning illness as to not go to school, embarrassed at the crass remarks that would be hurled your way. T'was a tad torturous, to tell the truth.

For anyone engaging in sex, listen up. It's time to take the bull by the horns and get responsible for your health. Sure, at the beginning of your sex life it's hard to see that this comes with the territory. But it does and you're better off realizing that now, before you become infected with something like herpes that can change your life forever.

Genital herpes is something that cannot be hidden from a lover. They are also unsightly and painful. STD testing on a regular basis can keep you abreast of your health situation and alert you to any detrimental disease that you may have acquired during your sexual shenanigans. You owe it to your lover-if not yourself-to make sure that you are as healthy as possible. Protection is the way to go. But too many times, too many of us neglect that fact when in the throes of passion (ie: horny!)

Let's take a look at herpes and their diagnosis and treatment:

What are herpes exactly? Well, herpes is a collection of similar viruses (remember that viruses CANNOT be cured but only kept under control). The most common herpes viruses are HSV 1 and HSV 2. The HSV stands for "Herpes Simplex Virus" with the former being oral herpes and latter being genital herpes.

What are the symptoms? As mentioned earlier in this article, the symptoms are a series of blisters that break and scab over causing painful sores.

Does everyone who is infected show signs and symptoms? Surprisingly the answer to this question is "no." Many people are infected with the virus and do not break out in sores. These infected individuals may still infect others who WILL break out in sores. This is another reason why herpes testing so important for everyone having sexual relations.

What is the testing procedure? There are several different tests for herpes. They include the herpes viral culture, the herpes antigen test and the polymerase chain reaction test. It may all sound very confusing but it is not. Still, it is only at a certified STD Clinic that the doctor can choose the best test for you, administer it, and get you the results quickly. If you test positive the doctor can offer the best choice of treatment, as well.

What are the treatments? Again, because herpes is a virus and not bacteria, once you are infected, there is no getting rid of it totally. The best a doctor can do is to keep your symptoms (the painful sores) from forming with any regularity. Thankfully, there are medicines available today that make this possible.




For those of you located in the NYC area, log onto Herpes testing NYC to arrange and appointment with this discreet and highly regarded STD Clinic Dial 1-212-696-5900 for more information and remember that testing for all STDs is your best bet for remaining healthy and happy.